Výsledky vyhledávání - "Josie Montegaard"

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Autor: Austin I. Kim, Caron A. Jacobson, Zixu Wang, Ann S. LaCasce, Samantha Pazienza, Jessica Lowney, Jennifer R. Brown, Matthew S. Davids, Jennifer L. Crombie, Matthew Weinstock, David C. Fisher, Svitlana Tyekucheva, Jon E. Arnason, Philippe Armand, Josie Montegaard, Samuel Y. Ng, Benjamin L. Lampson, Victoria Patterson

Publikováno v: The Lancet Oncology. 22:1391-1402

Both continuous therapy with acalabrutinib and fixed-duration therapy with venetoclax-obinutuzumab are effective for previously untreated chronic lymphocytic leukaemia. We hypothesised that frontline time-limited, minimal residual disease (MRD)-guide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8fbe0b0a6328ba157009a8ae5a8c103
https://doi.org/10.1016/s1470-2045(21)00455-1

Zobrazit plný text záznamu

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Autor: Kerry A. Rogers, Sarah K Renner, Josie Montegaard, Caron A. Jacobson, Matthew S. Davids, Svitlana Tyekucheva, Udochukwu O Ihuoma, Samantha Pazienza, Catherine J. Wu, David C. Fisher, Philip A. Thompson, Timothy Z. Lehmberg, Zixu Wang, Jennifer R. Brown, Erin M. Parry

Publikováno v: Blood

Richter syndrome (RS) of chronic lymphocytic leukemia (CLL) is typically chemoresistant, with a poor prognosis. We hypothesized that the oral Bcl-2 inhibitor venetoclax could sensitize RS to chemoimmunotherapy and improve outcomes. We conducted a sin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39c967818ae548984b4d6acf98e42f0a
https://pubmed.ncbi.nlm.nih.gov/34788401

Zobrazit plný text záznamu

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

Autor: Karen Francoeur, Matthew S. Davids, Oreofe O. Odejide, Josie Montegaard, Jon E. Arnason, Mikaela McDonough, David C. Fisher, Brandon Lee, Svitlana Tyekucheva, Jennifer R. Brown, Philippe Armand, John Hanna

Publikováno v: Leukemia

Fludarabine, cyclophosphamide, and rituximab (FCR) is highly effective initial therapy for younger patients with chronic lymphocytic leukemia (CLL); however, most eventually relapse. Duvelisib is a delta/gamma PI3K inhibitor approved for relapsed/ref

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bdeeb84b2cfda279965ba06fcfbef78
https://pubmed.ncbi.nlm.nih.gov/32820271

Zobrazit plný text záznamu

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

Publikováno v: Blood. 138:640-640

Introduction FCR remains the only therapy other than allo transplant proven to provide a significant chance of functional cure with very long term follow-up for young, fit patients with mutated IGHV CLL. Given the excellent efficacy and tolerability

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8881bd383e9ac1ba9798328e42fb1723
https://doi.org/10.1182/blood-2021-146624

Zobrazit plný text záznamu

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

Autor: Karen Francoeur, Matthew S. Davids, Jacob D. Soumerai, Alexandra Savell, Jennifer R. Brown, Jessica Lowney, Austin I. Kim, Zixu Wang, David C. Fisher, Josie Montegaard, Allan Louie Cruz, Lisa L. Brennan, Sigrid Berg, Svitlana Tyekucheva, Jennifer L. Crombie, Jon E. Arnason

Publikováno v: Blood. 136:46-47

Introduction: The MURANO study demonstrated that venetoclax (VEN) plus rituximab is an effective regimen for pts with relapsed/refractory (R/R) CLL, but included 2 years of treatment and an infusional component (Seymour et al., NEJM, 2018). Duvelisib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51ebaf60022e43785dd971d8989f736a
https://doi.org/10.1182/blood-2020-138811

Zobrazit plný text záznamu

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Autor: Ann S. LaCasce, Victoria Patterson, Jennifer L. Crombie, Matthew S. Davids, Jennifer R. Brown, Philippe Armand, Jon E. Arnason, Samuel Ng, Benjamin L. Lampson, Matthew Weinstock, Austin I. Kim, David C. Fisher, Svitlana Tyekucheva, Caron A. Jacobson, Josie Montegaard, Samantha Pazienza, Jessica Lowney

Publikováno v: Blood. 136:20-21

Background Despite active frontline regimens including venetoclax (V) plus obinutuzumab (O) and continuous BTK inhibitors (BTKi), the outcomes for some CLL patients (pts) remain suboptimal. The ibrutinib (I) plus V doublet and IVO triplet are active

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f762069db83dd39811fdda97d837c56
https://doi.org/10.1182/blood-2020-139864

Zobrazit plný text záznamu

A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome

Autor: Matthew S. Davids, Jennifer R. Brown, Michael Rocchio, Udochukwu O Ihuoma, Philip A. Thompson, Samantha Pazienza, Caron A. Jacobson, Kerry A. Rogers, Sarah K Renner, Josie Montegaard, David C. Fisher, Svitlana Tyekucheva

Publikováno v: Journal of Clinical Oncology. 38:8004-8004

8004 Background: While therapeutic options for CLL have improved, patients (pts) who develop Richter’s Syndrome (RS) still have a poor prognosis. Chemoimmunotherapy regimens such as R-EPOCH lead to CR in about 20% of RS pts, but PFS/OS is typically

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03683af73da2cc85bc4968dae751d8e9
https://doi.org/10.1200/jco.2020.38.15_suppl.8004

Zobrazit plný text záznamu

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Autor: Jennifer L. Crombie, Jennifer R. Brown, Jon E. Arnason, Austin I. Kim, Philippe Armand, Svitlana Tyekucheva, Josie Montegaard, Victoria Patterson, Matthew S. Davids, Reid W. Merryman, Eric D. Jacobsen, David C. Fisher, Benjamin L. Lampson, Ann S. LaCasce, Jessica Lowney, Caron A. Jacobson

Publikováno v: Blood. 134:32-32

Backgound Venetoclax (V) plus obinutuzumab (O) regimen is active as frontline CLL treatment; a little over half of patients (pts) will achieve undetectable minimal residual disease in the bone marrow (BM-uMRD) with one year of time-limited therapy (F

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::06c4169d0859fd48c8ffbcce84583741
https://doi.org/10.1182/blood-2019-127506

Zobrazit plný text záznamu

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Autor: Matthew S. Davids, Josie Montegaard, Jacob D. Soumerai, David C. Fisher, Jennifer L. Crombie, Jon E. Arnason, Mark Choiniere, Karen Francoeur, Alexandra Savell, Jennifer R. Brown, Svitlana Tyekucheva

Publikováno v: Blood. 134:1763-1763

Introduction: Duvelisib (DUV), an oral inhibitor of PI3K-δ/γ, and venetoclax (VEN), an oral inhibitor of BCL-2, are both approved for relapsed/refractory (R/R) CLL. We previously found that PI3K-δ inhibition sensitizes CLL cells to ex vivo BCL-2 i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be437684625c8f33be9f0529caa8f23c
https://doi.org/10.1182/blood-2019-127343

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání